Foghorn Therapeutics Inc.
FHTX
$3.87
$0.164.31%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.88M | -21.66M | -15.85M | -17.94M | -18.83M |
| Total Depreciation and Amortization | 238.00K | 802.00K | 852.00K | 851.00K | 827.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.56M | 6.79M | 3.07M | 3.81M | 3.32M |
| Change in Net Operating Assets | -8.19M | -8.20M | -6.94M | -7.72M | -9.28M |
| Cash from Operations | -25.27M | -22.27M | -18.86M | -21.00M | -23.97M |
| Capital Expenditure | -- | 0.00 | 0.00 | -22.00K | -28.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -17.72M | 13.23M | 35.57M | 33.86M | 29.43M |
| Cash from Investing | -17.72M | 13.23M | 35.57M | 33.83M | 29.40M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 50.09M | 581.00K | 49.00K | 254.00K | 139.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -316.00K | -- | -- | -- | -- |
| Cash from Financing | 49.77M | 581.00K | 49.00K | 254.00K | 139.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.79M | -8.46M | 16.76M | 13.09M | 5.57M |